Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Official title: Endothelial Inflammation, Src Kinase Dysregulation, and Fibrosis in Early Pulmonary Arterial Hypertension
Funded at Brigham and Women's Hospital · NIH-11411210 · Data updated 2026-11-12
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 15, 2025 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $739,659 |
| NIH project number | 5R01HL176637-02 |
| Project ID | NIH-11411210 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with or at risk for pulmonary arterial hypertension, especially those with inflammatory connective tissue disease–associated PAH, could be relevant for future translational work or trials arising from this research.
✕Less likely to help
Individuals without PAH or those not connected to the study’s inflammatory CTD context may not directly benefit from this research.
What this research studies
This project aims to understand how endothelial inflammation drives fibrosis and vessel remodeling in early PAH using a model of endothelial inflammation and human PAH cell data. It focuses on the role of C-terminal Src kinase (Csk) as a mediator of endothelial dysfunction and fibrosis, and on identifying molecular pathways connected to inflammatory CTD risk. By linking network medicine analysis with experimental models, the study seeks to reveal targets that could prevent progression before severe disease develops. The findings could inform future therapies to reduce right heart strain and improve outcomes in patients with inflammatory CTD-associated PAH.
Why it matters
Potential benefit: If successful, the research could identify new targets to halt or slow vascular remodeling in early PAH, potentially improving survival and quality of life for patients.
How similar studies have gone: Prior work has shown that targeting inflammatory pathways and Src signaling can influence vascular remodeling in PAH models, supporting potential translational relevance here.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Wertheim, Bradley — Brigham and Women's Hospital
- Study coordinator: Wertheim, Bradley
Related research
Other NIH-funded projects on the same topics.
-
Investigating how protein processes affect blood vessel health in early pulmonary arterial hypertension.
This study is looking at how a process called ubiquitination affects the thickening of blood vessels in the lungs, which can lead to early pulmonary arterial hypertension (PAH) and heart problems, with the goal of finding new ways to help patients feel better.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.